Hudson Technologies, Inc. (NASDAQ: HDSN) gained 8.84% to $1.60 in the morning hour after the company announced that the Environmental Protection Agency (EPA) has issued a proposed rule that would reduce the allowances for U.S. consumption and production of Hydrochlorofluorocarbon-22 (HCFC-22).
Saba Software, Inc. (NASDAQ: SABA) climbed 14.04% to $8.45 in the morning hour after the company reported financial results for its second quarter ended November 30, 2011. Total GAAP revenues in the second quarter of fiscal year 2012 were $30.4 million, up 4% from $29.2 million in the same quarter last year. GAAP loss per share was $0.16 in the second quarter of fiscal year 2012 compared to a loss per share of $0.03 in the same period last year.
Exide Technologies (NASDAQ: XIDE) gained 9.25% to $3.07 in the morning hour. The 52 week trading range for the company is $2.22 – $12.68. In the last one year, the company has plunged 68%. Exide is a provider of stored electrical energy solutions, and is a manufacturer and supplier of lead-acid batteries for transportation and industrial applications worldwide.
DURECT Corporation (NASDAQ: DRRX) plunged 36.22% to $0.753 in the early hour after the company announced today top-line results from the U.S. pivotal Phase III clinical study for POSIDUR known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) plummeted 14.40% to $4.40 in the early hour after the company announced today that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per share.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial adviser.